WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p>
\nABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party.<\/p>
\nThe filing relating to this sale can be viewed in the AMF's database of decisions and financial information (BDIF) at the following address: https:\/\/bdif.amf-france.org\/fr\/details\/2026DD1117613<\/a>.<\/p> \nWith the support of its main shareholder, ABL, ABL Diagnostics is continuing its efforts to enhance its visibility among all stakeholders (investors, partners, customers, and employees).<\/p> \nAbout ABL Diagnostics (ABLD)<\/b><\/p> \nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p> \nABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.<\/p> \nABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.<\/p> \nAn expanding portfolio of microbiology products:<\/b><\/p> \nIntegrated Solutions<\/b><\/p> \nABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD \u2013 ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.<\/p> \nABL Diagnostics SA<\/b> \nTel : +33 (0)7 83 64 68 50\n WOIPPY, France–(BUSINESS WIRE)–Regulatory News:\n
\n
\n
\nABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-16368","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/16368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16368"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/16368\/revisions"}],"predecessor-version":[{"id":16369,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/16368\/revisions\/16369"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}